The impact of ideglira in treatment simplification in older adults with type 2 diabetes mellitus already on insulin therapy: The stop study
Authors' conclusion
IdegLira represents a viable option in deintensifying insulin therapy in an elderly population.
Study context
- Population
- Elderly insulin-treated persons with T2D (46F, age 77 ± 7 yrs, HbA1C 7.5 ± 1.0, diabetes duration 21 ± 10 yrs; 75 % on basal/bolus insulin)
- Participants
- 96 persons
- Exposure
- Switch to IdegLira vs prior insulin therapy
- Outcome
- FPG and HbA1c
- Follow-up
- 6 months (T6) vs T0
Methodological detailsreal world, single center, proof-of-concept
- Real world
- Single center
- Proof-of-concept
Main finding
As reported in the abstract
- FPG significantly decreased at T6 vs T0, as did HbA1c
Observational data: associations, not effects.
Further findings
Insulin regimen
- Rapid acting insulin interrupted
- 85 % of patients
Safety
Proportion of persons with L1 hypoglycemia — T3 vs T0
P = 0.004
| Outcome | T0 | T3 | T6 | IR (95 % CI) | P value |
|---|---|---|---|---|---|
| Level 1 (L1) hypoglycemia ratesT3 vs T0 | 0.24 (0.11–0.58) | P < 0.001 | |||
| Level 1 (L1) hypoglycemia ratesT6 vs T0 | 0.08 (0.02–0.34) | P < 0.001 | |||
| Level 2 (L2) hypoglycemia rates · T3T3 vs T0 | 0.04 (0.01–0.32) | P < 0.001 | |||
| Proportion of persons with L1 hypoglycemiaT6 vs T0 | P < 0.001 | ||||
| Incidence of L2 hypoglycemiaT3 vs T0 | 22.1 % | 1.16 % | 0 events | P < 0.001 |
Original publication
The impact of ideglira in treatment simplification in older adults with type 2 diabetes mellitus already on insulin therapy: The stop study. Diabetes Res Clin Pract. Published 31 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →